Aptose Biosciences Inc. (NASDAQ:APTO) Sees Significant Decrease in Short Interest

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 80,800 shares, a decline of 13.1% from the June 30th total of 93,000 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 66,400 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned about 0.16% of Aptose Biosciences at the end of the most recent quarter. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Price Performance

NASDAQ APTO traded up $0.01 during midday trading on Wednesday, hitting $0.58. 31,861 shares of the company traded hands, compared to its average volume of 78,345. The company has a market cap of $10.47 million, a PE ratio of -0.09 and a beta of 1.26. Aptose Biosciences has a 52 week low of $0.55 and a 52 week high of $5.10. The company’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $1.34.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.09. On average, research analysts predict that Aptose Biosciences will post -2.62 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 target price on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. StockNews.com began coverage on Aptose Biosciences in a report on Wednesday, July 24th. They set a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June 14th. Finally, Canaccord Genuity Group cut their price target on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Aptose Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.